Cell Signaling Technology, Inc. Announces Renewal of PhosphoScan(R) Proteomics Research Project for Lead Compound Biomarker Discovery

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today the renewal of a research agreement with Ortho-Biotech Oncology Research & Development (ORD), a Division of Janssen Pharmaceutica, N.V., under which CST will employ its patented PhosphoScan® and PTMScan™ technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors.